Data from the phase 3 BOND-003 trial (NCT04452591), presented at the 2025 American Urological Association Annual Meeting, demonstrated that intravesical cretostimogene grenadenorepvec (CG0070) is a ...

Ferring Pharmaceuticals presented the initial results from an ongoing Phase 3 trial (NCT05704244) in Japan assessing the efficacy and safety of ADSTILADRIN® (nadofaragene firadenovec-vncg) in patients ...

left her with uncomfortable spasms, increased frequency and urgency. Despite undergoing bladder stretching and Botox treatments, these methods were unsuccessful. The mother of one said ...

bladder spasm, urgency to urinate, chills, dysuria, pyrexia, and urinary incontinence. There were no Grade 4 or 5 TEAEs, no treatment-related deaths, and no new safety signals reported with long ...

The treatment has an acceptable safety profile ... symptoms reflect urinary tract instrumentation effects, such as bladder spasm, burning sensation, and urinary tract infection.

Ferring is leading the future in uro-oncology treatment with ADSTILADRIN at ... triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria ...

No patients discontinued treatment due to TRAEs ... symptoms reflect urinary tract instrumentation effects, such as bladder spasm, burning sensation, and urinary tract infection.

Ferring Pharmaceuticals announced today the U.S. Food and Drug Administration (FDA) approved a state-of-the-art drug product manufacturing hub in Parsippany, NJ, for its intravesical non-replicating ...

First results from a Phase 3 trial conducted across 25 centers in Japan were presented at the Annual Meeting of the Japanese Urological Association ...

No grade 3 or higher treatment-related adverse events (TRAEs) or deaths occurred. The most common TRAEs occurring in at least 10% of patients included bladder spasm, pollakiuria, micturition ...